Washington, D.C. — June 11, 2025 — Commitment to Seniors, a project of American Commitment, strongly urges the Senate not to include the AARP-backed “Most Favored Nation” (MFN) drug pricing model in the One Big Beautiful Bill Act. If implemented, this price-fixing policy will have a devastating impact on America’s prescription drug market, which older Americans heavily depend on.
MFN would import foreign price controls by tying U.S. drug prices to those of other countries, which is the wrong response to the real problem of other rich countries free-riding on innovation financed by American consumers. We need to beat foreign price controls, not join them, or we will undermine critical research and development (R&D) of lifesaving therapies and treatments for chronic diseases such as cancer and Alzheimer’s.
The Senate must carefully consider these unintended consequences, reject efforts to include MFN in the reconciliation package, and prioritize alternative solutions to strengthen America’s health care system, such as demanding that foreign countries loosen their price control regimes in the context of ongoing trade negotiations and cracking down on the kickback schemes used by Pharmacy Benefit Managers (PBMs).
“Price controls in other countries have proven to lead to drug shortages, delayed access to new treatments, and decreased R&D. They survive only because the United States market drives global innovation,” said Phil Kerpen, President of American Commitment. “Linking U.S. prices to foreign prices is a disastrous response to free-riding, because it could eventually mean there is no moving vehicle developing new cures and treatments at all. Seniors deserve real health care reforms. MFN is not the answer.”